Acute invasive fungal rhinosinusitis (AifRS) can spread beyond the sinonasal cavity. it is necessary to analyze the association between the specific site involved in the extrasinonasal area and the survival rate to predict patient prognosis. We investigated 50 patients who had extrasinonasal lesions on preoperative gadolinium (Gd)-enhanced magnetic resonance imaging (MRi) scan and underwent wide surgical resection of AIFRS. The specific sites with loss of contrast enhancement (LoCE) on Gd-enhanced MRI were analyzed for AIFRS-specific survival rate. The most common underlying disease was diabetes mellitus followed by hematological malignancy. the most common symptoms were headache and facial pain. Seven patients (14.0%) expired because of AIFRS progression. Poor prognosis was independently associated with Loce at the skull base on preoperative MRi (HR = 35.846, P = 0.004). In patients with AifRS extending to the extrasinonasal area, Loce at the skull base was an independent poor prognostic factor.
Results
Headache and facial pain are the most common symptoms in AfiRS patients. Table 1 summarizes the patients' clinical characteristics. Thirty male (60.0%) and twenty (40.0%) female patients were included. Their median age was 63.5 years (range, 12-84 years), and 32 (64.0%) patients were ≥60 years old. The median follow-up period was 9.2 months (range, 0.3-110.5 months). Twenty-eight (56.0%) patients had DM, and 15 (30.0%) patients had hematological malignancies. Eight (16.0%) patients had two or more underlying diseases, whereas four elderly (8.0%) patients had no underlying disease. The most common symptom was headache in 21 (42.0%) patients, followed by facial pain in 17 (34.0%) patients. Neutropenia (absolute neutrophil count ≤500/ mm 3 ), severe lymphocytopenia (lymphocyte count ≤100 cells/mm 3 ) , and monocytopenia (monocyte count ≤10 cells/mm 3 ) at the time of diagnosis 5 were identified in six (12.0%), eight (16.0%), and four (8.0%) patients, respectively. Seven (14.0%) patients had evidence of pulmonary fungal infection on chest CT at the time of AIFRS diagnosis.
All patients had definite invasion of fungus to mucosa, bone, vessel, and/or adjacent tissue on histopathological analysis. Thirty-three (66.0%) patients were mucormycosis, 16 (32.0%) patients were aspergillosis, and one patient's infectious organism was not clarified. However, only 21 (42.0%) patients were positive in fungal culture. Thirty-four (68.0%) patients underwent preoperative empirical antifungal medication. Twenty-three patients with mucormycosis, and the patient infected with unknown species were treated with amphotericin B/liposomal amphotericin B-based therapy. The 16 patients with aspergillosis were treated with voriconazole. The median duration of antifungal treatment was 98 days (range, 9-599 days).
A total of 31 (62.0%) patients underwent an endoscopic approach only, and 19 (38.0%) patients underwent either a sublabial approach or maxillectomy. The median number of operations was two (range, 1-5 times), and 26 (52.0%) patients underwent surgery more than once. There were no serious postoperative complications, such as CSF leakage or uncontrolled hemorrhage. Eight patients with invasive mucormycosis and a patient with invasive aspergillosis who had preoperative LoCE lesions in the orbit underwent orbital exenteration, and all of them were histopathologically confirmed to have fungal invasion of orbital contents. Of them, three patients expired because of progression of residual lesions at the orbital apex and body of the sphenoid bone, respectively. An intracranial fungal abscess was identified in six (12.0%) patients on preoperative MRI, and two of them expired because of progression of residual lesions at body of the sphenoid bone and temporal lobe.
These clinical factors were not significantly associated with AIFRS-specific survival rate (all P > 0.05), except for well-controlled DM (P = 0.038, Table 2 ).
Loce at the skull base was an independent poor prognostic factor in AifRS patient. After discontinuing the antifungal therapy, patients who did not show any evidence of AIFRS progression by endoscopy and MRI and did not relapse were judged to have been cured. According to this criterion, of 50 patients, 37 (74.0%) were cured of AIFRS at last follow-up (range, 0.3-110.5 months). 6 (12.0%) patients had no remnant lesion on endoscopy and MRI but died from progression of underlying disease or other infections during the administration of the antifungal agent. Seven (14.0%) patients expired within 100 days because of progression of AIFRS to the brain, which led to meningitis, cerebral hemorrhage, and/or infarction and brain edema. The incomplete resection sites in these seven patients comprised the body and/or greater wing of the sphenoid bone, orbital apex, and adjacent large area of dura. www.nature.com/scientificreports www.nature.com/scientificreports/ When the relative risk of AIFRS-specific mortality according to the subsite of preoperative LoCE lesion was analyzed, the involvement of the orbit [hazard ratio (HR) =4.862, P = 0.038)], skull base (HR = 67.979, P = 001), cavernous sinus (HR = 9.873, P = 003), infratemporal fossa (HR = 11.238, P = 0.002), and meninges (HR = 11.238, P = 0.002) significantly increased the mortality rate in the univariate analysis (Table 3 ). In the multivariate analysis, only skull base with LoCE was an independent prognostic subsite [HR = 35.846; 95% confidence interval (CI), 3.193-402.414, P = 0.004, Table 4 , Figs. 1 and 2].
Discussion
The treatment strategy for AIFRS involves extensive removal of necrotic lesions combined with antifungal therapy. AIFRS confined to the sinonasal cavity can be readily treated by endoscopic sinus surgery. However, when AIFRS extends beyond the sinonasal cavity, the surgeon has to predict the prognosis and determine the extent of surgical removal. In this study, the involvement of the skull base, particularly in the body and/or greater wing of the sphenoid bone and orbital apex, was identified as an independent poor prognostic factor in AIFRS extending to the extrasinonasal area. The presenting symptoms of AIFRS are variable. A systematic review of AIFRS showed that the most common symptom was facial swelling (64.5%), followed by fever (62.9%), nasal congestion (52.2%), ophthalmoplegia (50.9%), facial pain (46.8%), and headache (46.3%) 6 . Conversely, a previous study reported that the most common symptoms were headache (61.1%), facial pain (55.6%), and ophthalmoplegia (33.3%) 11 . In another study, fever was the predominant presenting symptom, followed by facial pain, nasal obstruction, and rhinorrhea 12 . In the present study, facial pain, headache, and/or ophthalmoplegia were the most common symptoms, whereas nasal symptoms, including rhinorrhoea and nasal obstruction, occurred in only approximately 28% of patients. Moreover, fever was present in only nine (16.0%) patients, which was relatively low for a presenting symptom compared with those in other studies 6, 12 . Fever may be more common in patients with hematological malignancy given that four out of five patients with fever had hematological malignancy. This study included a relatively small proportion of hematological malignancies (30.0%) with more than half being DM, whereas 39.0% and 90.1% of hematological malignancies were included in other studies 6, 12 . Therefore, immunocompromised patients who complain of facial pain, headache, and/or ophthalmoplegia without other symptoms of sinusitis should be examined for the possibility of AIFRS.
The present study revealed that patients with well-controlled DM showed better AIFRS-specific survival as some previous studies, have shown that better prognosis was observed in patients with DM that can be rapidly managed 6, 7, 13 . However, advanced age and remission of hematological diseases at the time of AIFRS diagnosis were not significantly associated with AIFRS-specific survival rate in patients with AIFRS who underwent surgery. This result seems to be because the proportion of patients aged ≥60 years was relatively high (64.0%), and the proportion of patients with hematological diseases among those who died was relatively low (42.9%). www.nature.com/scientificreports www.nature.com/scientificreports/ Although some studies have demonstrated that invasive mucormycosis showed higher mortality compared with invasive aspergillosis 14, 15 , others have reported that the type of fungal organism was not associated with the survival rates of patients with AIFRS 6, 7 . We also found that there was no significant difference between the survival rate of invasive mucormycosis and that of aspergillosis. A recent multicenter study reported that atypical fungi, including Candida, Fusarium, and Alternaria, which are resistant to amphotericin B and other antifungal agents, were associated with poor survival rate 16 . Considering the efficacy of antifungal agents, our results may be because these organisms have individual susceptibilities to amphotericin B and voriconazole. In addition, approximately 70% of patients with suspected AIFRS received empirical antifungal therapy before diagnostic and therapeutic surgery. Therefore, empirical antifungal treatment may not affect the AIFRS-specific survival rate.
Preoperative and postoperative extrasinonasal LoCE lesions were significantly associated with AIFRS-specific survival rate. The present study confirmed that the presence of extrasinonasal LoCE reflecting a necrotic lesion, particularly at the skull base, was a poor independent prognostic factor of AIFRS-specific survival rate. In seven patients who expired because of the progression of AIFRS, extensive necrotic lesions of the body and/or greater wing of the sphenoid bone, orbital apex, and the adjacent large area dura were not completely resected. In our experience, fungal infections of soft tissue are sometimes treated with antifungal agents, whereas bone-infected fungi do not appear to be treated by antifungal agents alone. Postoperative endoscopic findings suggest that antifungal agents may be delivered from surrounding non-infected soft tissue to infected soft tissues because blood vessels and granulation tissue grow in adjacent healthy soft tissues, and some infected soft tissue can be removed at the clinic. However, infected bone may not be able to deliver antifungal agents because of thrombosis formation of penetrating vessels. The remaining lesions gradually spread to the adjacent area, eventually resulting in cerebrovascular injury and parenchymal damage. However, it is questionable as to whether surgery at these sites can be helpful for patients with AIFRS. These sites are adjacent to the cavernous sinus, internal carotid artery, and middle cranial fossa. Although focal necrotic lesions at these structures could be resected, extensive lesions could not be completely removed, and rather extensive resection might lead to serious morbidity, such as internal carotid artery injury, untreated CSF leakage, meningitis, or brain injury. Because fungi invading these structures also invaded paranasal sinuses, septum, turbinates, pterygopalatine fossa, and infratemporal fossa, a mucosal flap for skull base reconstruction, such as a nasoseptal flap, lateral nasal wall flap, and middle turbinate flaps, could not be used. These serious postoperative complications may significantly shorten the survival time.
Previous studies have shown that the involvement of brain, orbit, cavernous sinus, pterygopalatine fossa, and/ or palate may lead to a poor prognosis 6, 13, [16] [17] [18] [19] . However, our study showed that brain involvement is not associated with AIFRS-specific survival rate because four of six patients with intracranial fungal abscesses were successfully treated with antifungal agents and/or surgery. Furthermore, LoCE lesions in the orbit, cavernous sinus, infratemporal fossa, and meninges were significantly associated with AIFRS-specific survival rate in univariate analysis but not in multivariate analysis. A recent multicenter study also reported that orbit and intracranial involvement were not statistically significant prognostic factors 16 .
The present study included a small number of patients with AIFRS because of the rarity of this disease. Especially, the number of patients who died from AIFRS was small. Most of the patients could be successfully treated with surgical debridement combined with antifungal agents, probably because most of the suspected AIFRS patients were examined relatively quickly, underwent early MRI scans, and were operated upon when the extent of necrotic lesion was limited to a resectable area. In addition, this study was retrospective in design. However, based on our previous study 7 , we have identified a surgical strategy for AIFRS involving as complete as possible resection of LoCE lesions identified on preoperative Gd-enhanced MRI and additional resection of remaining or extended LoCE lesions identified on postoperative Gd-enhanced MRI. This consistent strategy may overcome the limitation of the small number of patients and retrospective design.
In conclusion, this study showed that patients with immunodeficiency who complain of facial pain, headache, and/or ophthalmoplegia should be suspected of having AIFRS. Although AIFRS has a relatively high mortality rate, complete resection of LoCE lesions identified on Gd-enhanced MRI can improve survival rates in patients with AIFRS. Under the provision of efficient antifungal agents and strict blood sugar control, the LoCE of the skull base was found to be an independent negative prognostic factor.
Methods
Study participants. In total, 69 patients were histologically diagnosed as having definite AIFRS and surgically treated between November 2002 and December 2018. All patients underwent surgery within 1 month of symptom onset (range, 1-29 days). Computed tomography (CT) and Gd-enhanced MRI were preoperatively performed. Endonasal endoscopic surgery was performed and procedures, including an additional sublabial approach, maxillectomy, orbital exenteration, and/or brain surgery, were performed as required. Postoperative MRI was performed to identify residual lesion and disease progression. An antifungal agent was administered before or after surgery according to the confirmation of the fungal species.
The extent of disease was defined as an enhanced lesion on Gd-enhanced MRI. To identify the specific extrasinonasal sites of disease associated with AIFRS-specific survival rate, nineteen patients whose disease was confined to the sinonasal cavity were excluded. The remaining 50 patients with preoperative disease beyond the sinonasal cavity, including the palate, orbit, skull base (bones structures including posterior table of frontal sinus, cribriform plate, ethmoid roof, and sphenoid bone that form the floors of the anterior, middle, and posterior cranial fossa), cavernous sinus, pterygopalatine fossa, infratemporal fossa, meninges, and brain, were included. Their clinical characteristics, preoperative and postoperative image findings, surgical findings, antifungal drug administration records, survival rate, and follow-up period were reviewed. The distribution of LoCE lesions identified on MRI were analyzed in the extrasinonasal areas.
www.nature.com/scientificreports www.nature.com/scientificreports/ ethics statement. This study was approved by the Institutional Review Board of the Asan Medical Center, which exempted the study from requiring individual patient consent. All procedures performed in studies were in accordance with the ethical standards of Institutional Review Board of the Asan Medical Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Statistical analysis.
The primary outcome of this study was disease-specific survival rate. The survival rates according to clinical factors were compared by using the log-rank test. Univariate and multivariate analyses of prognostic factors were performed by using Cox proportional hazards models. IBM ® SPSS ® Statistics for Windows, version 22.0 (IBM, Armonk, NY, USA) was used for all statistical analyses. Statistical differences were considered significant at P < 0.05.
